Summary
Boston Scientific Corporation (BSX) has filed its 2023 Annual Report (10-K/A) on February 20, 2024, reflecting their performance for the period ending December 30, 2023. While the provided excerpt focuses on exhibit information, a full 10-K filing would detail the company's financial performance, strategic initiatives, risk factors, and management's discussion and analysis. Investors should review the complete filing to understand BSX's revenue growth, profitability trends, debt levels, and any significant changes in its product portfolio or market position. Key areas for investor attention in the full report typically include the company's performance across its various segments (e.g., Cardiovascular, MedSurg, Pelvic Health, Neuromodulation), any notable acquisitions or divestitures, ongoing research and development efforts, and the competitive landscape. The filing also contains crucial information on the company's outlook and forward-looking statements, which are essential for assessing future growth prospects and potential risks.
Financial Highlights
51 data points| Revenue | $14.24B |
| Cost of Revenue | $4.34B |
| Gross Profit | $9.90B |
| SG&A Expenses | $5.19B |
| Operating Expenses | $7.55B |
| Operating Income | $2.34B |
| Interest Expense | $265.00M |
| Net Income | $1.59B |
| EPS (Basic) | $1.08 |
| EPS (Diluted) | $1.07 |
| Shares Outstanding (Basic) | 1.45B |
| Shares Outstanding (Diluted) | 1.46B |
Key Highlights
- 1The filing is an Amendment (10-K/A) to the original 10-K, indicating potential updates or corrections to previously submitted information. Investors should be aware of the nature of these amendments.
- 2The report covers the fiscal year ending December 30, 2023.
- 3The filing includes the consent of Ernst & Young LLP as the independent registered public accounting firm, suggesting a standard audit process.
- 4Exhibit 31.1 is listed, which typically relates to CEO and CFO certifications regarding the effectiveness of internal control over financial reporting.
- 5The excerpt highlights Part IV, Item 15, focusing on Exhibits and Financial Statement Schedules, which are crucial components of a comprehensive annual report.
- 6Investors should seek the full 10-K filing to access detailed financial statements, management's discussion and analysis, risk factors, and other critical disclosures.